With the emergence and long-term Impact of COVID-19, the Global Cardiac Biomarkers Market is to reach USD 47.75 Billion by 2030
Bizwit Research & Consulting LLP’s Recent Analysis on Global Cardiac Biomarkers Market is poised to raise up to USD 47.75 Billion by 2030. Cardiac biomarkers are molecules released into the bloodstream in response to heart damage or stress. The assessment of these biomarkers is a valuable tool in the diagnosis of conditions such as Acute Coronary Syndrome (ACS) and cardiac ischemia, both of which are characterized by inadequate blood supply to the heart. Additionally, tests for cardiac biomarkers serve to evaluate an individual’s risk of developing these conditions and are instrumental in monitoring and managing individuals with suspected ACS and cardiac ischemia.
The increasing demand for rapid diagnostic tests, the rise in initiatives to promote heart health, and regular screening for CVDs, along with the increasing aging population are the key factors that are fueling the demand for cardiac biomarkers across the globe. The global prevalence of CVDs, including heart attacks and heart failure, is increasing, driving the demand for cardiac biomarker tests to aid in diagnosis and monitoring. According to the World Health Organization (WHO), it was estimated that cardiovascular diseases (CVDs) are recorded as the leading cause of death around the world, which takes an estimated 17.9 million lives annually.
Moreover, the surge in demand for Point-of-Care (POC) cardiac diagnostics, as well as the growing demand for rapid diagnostic tests present various lucrative opportunities over the forecast years. However, the complexities associated with cardiac biomarker tests and the stringent regulatory frameworks are challenging the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Cardiac Biomarkers Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of a well-established healthcare system and the widespread adoption of cardiac biomarkers as a diagnostic and predictive tool for various medical conditions. The increasing elderly population, often in need of biomarker testing to detect conditions such as acute myocardial infarction, is a driving force behind the demand for these testing products. Furthermore, the presence of key industry players such as Quidel Corporation and Danaher Corporation in the region is an additional contributing factor to the market’s growth.
Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing accessibility to advanced cardiac tests, ongoing modernization efforts, and rising disposable incomes are significant contributing factors. Moreover, the escalating prevalence of cardiovascular diseases (CVDs) in this region has led to a heightened need for enhanced diagnostic tools. Government funding for targeted disease research and increased healthcare spending are also playing crucial roles. In comparison to other developing nations, India stands out with a higher incidence of CVDs. This substantial disease burden is anticipated to fuel the demand for cardiac biomarker diagnostics, as they play a pivotal role in enabling the diagnosis, assessment, and treatment of CVDs.
The global Cardiac Biomarkers Market is highly competitive owing to the presence of several key manufacturers such as Abbott, Quidel Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Danaher Corporation, BIOMÉRIEUX, Bio-Rad Laboratories, Inc., Randox Laboratories Ltd., and others.
For further analysis on this or to request a sample copy of this report, please click the link mentioned below:
Key findings of the study suggest:
- Global Cardiac Biomarkers Market is anticipated to grow with a healthy growth rate of more than 14.6% over the forecast period 2023-2030.
- In the Application segment, acute coronary syndrome emerged as the leading market segment in 2022.
- North America is anticipated to drive regional growth owing to widespread adoption of cardiac biomarkers as a diagnostic and predictive tool for various medical conditions.
- Asia Pacific is expected to grow at a high CAGR followed by North America during 2023-2030.
Bizwit Research & Consulting has considered the following segments for the study:
By Type:
- Troponin
- CK-MB
- Myoglobin
- BNP and NT-proBNP
- Others
By Application:
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others
By End use:
- Laboratory Testing
- Point of Care Testing
Regional Outlook
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Korea
- Australia
- RoAPAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
To get a sample of this report or to purchase a copy of the study, you can directly contact us at: sales@bizwitresearch.com
About Us
Bizwit Research & Consulting LLP is a global provider of business intelligence & consulting services. The company has a strong primary base of key industry leaders along with the chain of industry analysts to analyze the market trends and its future impact in order to estimates and forecast different business segments and markets. Bizwit incorporate big data, expert analysis, and huge industry database to deliver client focused business consulting reports. Our analysts perform unbiased measurement and assessment of market opportunities to comprehend detailed market forecast. Our team of key opinion leaders evaluates the market size, growth prospects, end-use, applications, value & supply chain and top vendors in the industry to help the clients to take conversant business decisions without any vague assumptions.
Contact US
Global Business Development
Phone : +1 209 498-3066
Email: Sales@bizwitresearch.com
Website: www.bizwitresearch.com
